https://www.selleckchem.com/products/trometamol.html 001), but no difference was noted for the PT. Multivariable logistic regression analyses showed that a 0.1 increase of the SR of the FCU of the throwing arm (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.14-1.48) and PT of the throwing arm (OR 1.41, 95% CI 1.19-1.67) and the non-throwing arm (OR 1.31, 95% CI 1.12-1.54) was significantly associated with an increased prevalence of medial elbow injuries. High elasticities of the FCU of the throwing arm and PT of both the arms were observed in individuals with medial elbow injuries, and were associated with increased prevalence of medial elbow injuries. These findings may be characteristic of medial elbow injuries in youth baseball players. High elasticities of the FCU of the throwing arm and PT of both the arms were observed in individuals with medial elbow injuries, and were associated with increased prevalence of medial elbow injuries. These findings may be characteristic of medial elbow injuries in youth baseball players. D-penicillamine (D-pen) is a copper-chelating drug and has immune-modulatory properties. D-pen is used to treat rheumatoid arthritis, Wilson's disease, and kidney stones (cystinuria). However, associated adverse events (AEs) of D-pen treatment are frequent and often serious. Therefore, a comprehensive assessment of the safety profile of D-pen is urgently needed. We identified and analyzed AEs associated with D-pen between April-1970 to July-2020 from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) databases and calculated the reported odds ratio (ROR) with 95% confidence intervals (CI) using the disproportionality analysis. A total of 9,150,234 AEs related to drugs were reported in the FAERS database, of which 542 were related to D-Pen. We report that D-pen was associated with dystonia (ROR 20.52; 95%CI 12.46-33.80), drug hypersensitivity (ROR 5.42; 95%CI 3.72-7.90), pancytopenia (ROR 10.20; 95%CI 5.61-18.56),